Genentech Colon Cancer Drug Works with 2nd Chemo

	Tweet

Genentech Inc. on Monday said its colon cancer drug Avastin extended the life of patients when used in combination with a chemotherapy regimen called FOLFOX4 more than the chemotherapy alone in a late stage clinical trial.

An interim analysis of the data showed patients taking the combination lived 12.5 months, compared to 10.7 months for those not getting the Genentech drug as a treatment. All patients in the trial had cancer that had spread to other parts of the body and had failed previous treatment.

Avastin in February was approved as a first-line treatment for the same type of colon cancer for use with another widely used chemotherapy regimen known as 5-FU. It prolonged life of patients by five months in those trials.

RELATED STORIES:
Abbott Says Withdrawing Attention Deficit Drug   FDA says open to more flexible clinical trials   US poll backs bigger gov’t role on drug prices   GlaxoSmithKline announces start of clinical trials to test two pandemic vaccines against the H5N1   Drugs must have warnings on suicide   New pill may help recovering alcoholics stay sober   Merck decided against 2000 Vioxx study   Bristol-Myers Squibb and Otsuka Pharmaceutical announce availability of 2 mg Abilify (aripiprazole)   Novartis tries to make UK hospitals use $1000 drug   E-prescribing Systems Can Boost Drug Cost Savings   Painkillers may raise heart attack risk slightly   Europe’s crisis spells more pain for drugmakers

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]